dr. sessa discusses atr inhibitors in brca-mutated tumors
Published 6 years ago • 290 plays • Length 1:57Download video MP4
Download video MP3
Similar videos
-
1:21
dr. sessa on the management of brca1/2 mutations in ovarian cancer
-
0:58
use of parp1-selective and atr inhibitors to target ddr signalling pathway
-
16:07
profound trial shows increased rpfs in mcrpc patients with brca1, brca2, and atm mutations
-
1:22
role of brca mutations in bc
-
3:52
understanding brca mutations and risk
-
3:00
what are the brca 1 and 2 genes and how do mutations effect me? with ddr tasha
-
1:22
dr. o'shaughnessy on the utility of capivasertib in targeting akt in breast cancer
-
1:56
arasens: dialuramide plus adt and docetaxel for metastatic hormone-sensitive prostate cancer
-
10:44
sequential hormonal blockade- casodex and proscar
-
4:21
standard protocol for the treatment of absssi
-
5:39
ductal carcinoma in situ: anastrozole versus tamoxifen
-
1:44
arasens: the addition of darolutamide to adt and docetaxel for the treatment of mhspc
-
8:18
esr mutations and resistance to endocrine therapy
-
4:45
oestrogen receptor ß ligand acts on cd11c cells to mediate protection in eae
-
1:03
azd2014 for treating er metastatic breast cancer – mode of action and trial results
-
4:18
case of the week: secondary angiosarcoma of the breast
-
2:37
eha 2022 | farhad ravandi, md | oral decitabine and venetoclax for aml #aml
-
3:08
case 2: er breast cancer
-
0:54
surpass: adp-a2m4cd8 t-cell receptor t-cell therapy and pembrolizumab in uc